Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6476MR)

This product GTTS-WQ6476MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6476MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9257MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ2657MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ13007MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ2942MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANB-011
GTTS-WQ2206MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ4060MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ8318MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ14173MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW